Start: March 2014
End: May 2017
Enrollment: 450
This Phase II study will evaluate the efficacy of the experimental drug T-817MA as a possible treatment for people with mild to moderate Alzheimer's disease. Its impact on cognition and daily functioning will be measured by standard tests.
Minimum Age: 55 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Toyama Chemical Co., Ltd.
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT02079909
An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health